1. Dulloo AG, Seydoux J, Girardier L., Peripheral
mechanisms of thermogenesis induced by ephedrine and caffeine in brown adipose
tissue. Int J Obes.15(5):317-326, 1991.
2. Astrup A, Lundsgaard C, Madsen J, Christensen
NJ. Enhanced thermogenic responsiveness during chronic ephedrine treatment in
man. Am J Clin Nutr. 1985 Jul; 42(1): 83-94.
3. Astrup A, Madsen J, Holst JJ, Christensen NJ
The effect of chronic ephedrine treatment on substrate utilization, the
sympathoadrenal activity, and energy expenditure during glucose-induced
thermogenesis in man. Metabolism 1986 Mar;35(3):260-265.
4. Sibley DR, Daniel K, Strader CD, Lefkowitz RJ
Phosphorylation of the beta-adrenergic receptor in intact cells: relationship to
heterologous and homologous mechanisms of adenylate cyclase desensitization.
Arch Biochem Biophys. 1987 Oct; 258(1): 24-32.
5. Toubro S, Astrup AV, Breum L, Quaade F. Safety
and efficacy of long-term treatment with ephedrine, caffeine and an
ephedrine/caffeine mixture. Int J Obes Relat Metab Disord Feb;17 Suppl
1:S69-S72, 1993.
6. Liu YL, Toubro S, Astrup A, Stock MJ.
Contribution of beta 3-adrenoceptor activation to ephedrine-induced
thermogenesis in humans. Int J Obes Relat Metab Disord 1995
Sep;19(9):678-685.
7. Nantel F, Bonin H, Emorine LJ, Zilberfarb V,
Strosberg AD, Bouvier M, Marullo S The human beta 3-adrenergic receptor is
resistant to short term agonist-promoted desensitization. Mol Pharmacol 1993
Apr;43(4):548-555.
8. Astrup A, Buemann B, Christensen NJ, Toubro S,
Thorbek G, Victor OJ, Quaade F. The effect of ephedrine/caffeine mixture on
energy expenditure and body composition in obese women. Metabolism
Jul;41(7):686-688, 1992.
9. Pasquali R, Casimirri F Clinical aspects of
ephedrine in the treatment of obesity. Int J Obes Relat Metab Disord;17 Suppl
1:S65-S68, 1993.
10. Kather H, Simon B., Biphasic effects of
prostaglandin E2 on the human fat cell adenylate cyclase. J Clin Invest
64(2):609-612, 1979.
11. Lonnqvist F, Arner P, Interactions between
adenylate cyclase inhibitors and beta-adrenoceptors in isolated human fat cells.
Biochem Biophys Res Commun 1989 Jun 15;161(2):654-660.
12. Kalsner S, Frew RD, Smith GM., Mechanism of
methylxanthine sensitization of norepinephrine responses in a coronary artery.
Am J Physiol 1975 Jun;228(6):1702-1707.
13. Astrup A, Toubro S, Cannon S, et al.
Caffeine: a double-blind, placebo-controlled study of its thermogenic,
metabolic, and cardiovascular effects in healthy volunteers. Am J Clin Nutr 1990
May;51(5):759-767.
14. Astrup A, Buemann B, Christensen NJ, Toubro
S, et al. The effect of ephedrine/caffeine mixture on energy expenditure and
body composition in obese women. Metabolism 1992 Jul;41(7):686-688.
15. Girardier L, Control systems in the defense
of body fat stores. Int J Obes Relat Metab Disord 1993 Feb;17 Suppl
1:S3-S8.
16. Dulloo AG, Jacquet J, Girardier L,
Autoregulation of body composition during weight recovery in human: the
Minnesota Experiment revisited. Int J Obes Relat Metab Disord 1996
May;20(5):393-405.
17. Dulloo AG, Miller DS, The thermogenic
properties of ephedrine / methylxanthine mixtures: Human studies. Int J Obes
1986; 10: 467-81.
18. Astrup A, Breum L, Toubro S, Hein P, Quaade
F, The effect and safety of an ephedrine/caffeine compound compared to
ephedrine, caffeine and placebo in obese subjects on an energy restricted diet.
A double blind trial. Int J Obes Relat Metab Disord 1992
Apr;16(4):269-277.
19. Toubro S, Astrup AV, Breum L, Quaade F.
Safety and efficacy of long-term treatment with ephedrine, caffeine and an
ephedrine/caffeine mixture. Int J Obes Relat Metab Disord 1993 Feb;17 Suppl
1:S69-S72.
20. Astrup A, Toubro S, Cannon S, Hein P, Madsen
J. Thermogenic synergism between ephedrine and caffeine in healthy volunteers: a
double-blind, placebo-controlled study. Metabolism 1991
Mar;40(3):323-329.
21. Dulloo AG, Miller DS., Aspirin as a promoter
of ephedrine-induced thermogenesis: potential use in the treatment of obesity.
Am J Clin Nutr 1987 Mar;45(3):564-569.
22. Horton TJ, Geissler CA., Aspirin potentiates
the effect of ephedrine on the thermogenic response to a meal in obese but not
lean women. Int J Obes 1991 May;15(5):359-366.
23. de Jonge L, Bray GA, The thermic effect of
food and obesity: a critical review. Obes Res 1997 Nov;5(6):622-631.
24. Daly PA, Krieger DR, Dulloo AG, Young JB,
Landsberg L Ephedrine, caffeine and aspirin: safety and efficacy for treatment
of human obesity. Int J Obes Relat Metab Disord 1993 Feb;17 Suppl
1:S73-S78.
25. Breum L, Pedersen JK, Ahlstrom F,
Frimodt-Moller J, Comparison of an ephedrine/caffeine combination and
dexfenfluramine in the treatment of obesity. A double-blind multi-center trial
in general practice. Int J Obes Relat Metab Disord 1994
Feb;18(2):99-103.
26. Astrup A; Toubro S; Cannon S; Hein P; Madsen
J Thermogenic synergism between ephedrine and caffeine in healthy volunteers: a
double-blind, placebo-controlled study. Metabolism 1991 Mar;
40(3):323-9.
27. Choo J, Horan M, Litlle R, and Rothwell N.
Anabolic effects of Clenbuterol on skeletal muscle are mediated by
beta2-adrenoreceptor activation. Am J Physiol 1992; 263:E50-E56.
28. Guentert TW, Buskin JN, Galeazzi RL Single
dose pharmacokinetics of mabuterol in man. Arzneimittelforschung
1984;34(11A):1691-1696.
29. Morgan J. Clinical Pharmacokinetics of
Beta-Agonists. Clin Pharmacokinet 1990 Apr;18(4):270-294.
30. Martineau L, Horan MA, Rothwell NJ, Little
RA. Salbutamol, a beta 2-adrenoceptor agonist, increases skeletal muscle
strength in young men. Clin Sci (Colch) 1992 Nov;83(5):615-621.
31. Caruso J, Signorile J, Perry A, et al. Time
Course Changes in Contractile Strength Resulting From Isokinetic Exercise and
Beta2 Agonist Administration. J. Strength Condition. Res. 1997;
11(1):8-13.
32. Rosenbaum M, Malbon CC, Hirsch J, Leibel RL.
Lack of beta 3-adrenergic effect on lipolysis in human subcutaneous adipose
tissue. J Clin Endocrinol Metab 1993 Aug;77(2):352-355.
33. MacIntyre DE. Human Beta-adrenergic receptor
agonists: identification and in vivo evaluation in the rhesus monkey.
Proceedings of the 1996 International Congress on Anti-Obesity Drug Targets,
Cambridge, MA, 9-11 December. Little Falls, NJ: International Quality and
Productivity Center.
34. Meyers DS, Skwish S, Dickinson KE, et al.
Beta 3-adrenergic receptor-mediated lipolysis and oxygen consumption in brown
adipocytes from cynomolgus monkeys. J Clin Endocrinol Metab 1997
Feb;82(2):395-401.
35. Danforth E, Himms-Hagen J. Obesity and
diabetes and the beta-3 adrenergic receptor. Euro J Endocrin 1997;
136:362-365.
36. Yoshida T, Umekawa T, Kumamoto K, et al. Beta
3-Adrenergic agonist induces a functionally active uncoupling protein in fat and
slow-twitch muscle fibers. Am J Physiol 1998 Mar;274(3 Pt
1):E469-E475.
37. Abe H, Minokoshi Y, Shimazu T. Effect of a
beta 3-adrenergic agonist, BRL35135A, on glucose uptake in rat
skeletal muscle in vivo and in vitro. J Endocrinol 1993
Dec;139(3):479-486